Abstract
We analyzed published studies on the efficacy and safety of the third dose of the COVID-19 vaccine in various general population settings. We conducted systematic searches of PubMed and EMBASE for series published in the English language through November 15, 2021, using the search terms “third” or “booster” or “three” and “dose” and “COVID-19” or “SARS-CoV-2.” All articles were selected according to the MOOSE guidelines. The seroconversion risk after third doses was descriptively expressed as a pooled rate ratio ([seroconversion rate after the third dose]/[seroconversion rate after the second dose]). The search returned 30 studies that included a total of 2 734 437 vaccinated subjects. In more than 2 700 000 Israeli patients extracted from the general population, the reduction in the risk of infection ranged from 88% to 92%. Conversion rates for IgG anti-spike ranged from 95% to 100%. In cancer or immunocompromised patients, mean IgG seroconversion was 39.4% before and 66.6% after third doses. A third dose seems necessary to protect against all COVID-19 infection, severe disease, and death risk.
Keywords: COVID-19; booster; third dose; vaccination.
【저자키워드】 COVID-19, vaccination, booster, third dose, 【초록키워드】 IgG, COVID-19 vaccine, vaccination, Cancer, Immunocompromised patients, risk, Seroconversion, COVID-19 infection, Patient, death, Efficacy and safety, General population, Anti-spike, dose, risk of infection, severe disease, English language, conversion rate, article, doses, PROTECT, selected, analyzed, conducted, subjects, expressed, reduction in, returned, ranged, pooled rate, 【제목키워드】 SARS-CoV-2, systematic review, dose,